Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive disease that is mainly caused by smoking. The best way to inhibit disease progression is smoking cessation.Patients with COPD are known to be more nicotine dependent than other smokers and therefore face more difficulties to quit smoking. Patients who receive pharmacological smoking-cessation treatment are more likely to stop smoking. However, it is unknown to which extent this treatment is actually offered to smokers with COPD.
Aim: The aim of this study was to describe the use of smoking-cessation medicine among Danish patients with COPD.
Materials and Methods: The study was designed as a retrospective, register-based, non-interventional study. All Danish patients with COPD (ICD-10-code J 44 Chronic obstructive pulmonary disease) between 2009 and 2015 were included. Those who had collected prescribed smoking-cessation medicine were compared to those who had not.
Results: We found that 12 % of patients with COPD collected a prescription on smoking-cessation medicine during the 8-year study period. We also found that patients with COPD have a higher likelihood of collecting smoking cessation medicine if they are younger, female, lives alone or are habituated away from the capital.
Conclusion: There is substantial room for improvement in the pharmacological smoking cessation treatment of Danish patients with COPD. In-depth knowledge on which factors that contribute to the choice of smoking-cessation method will possibly allow for a more personalized guidance of patients with COPD.
Footnotes
Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3056.
This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2020